TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3134314
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment placed on the chest
Study: 3134314
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment placed on the pelvis
Study: 8661572
Drug: No-drug control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug control group
Study: 10390554
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of dicyclomine chlorhydrate
Study: 10390554
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of dicyclomine chlorhydrate
Study: 8654625
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue treatment (6 SC implants of 3.6 mg goserelin acetate depot every 28 days for 6 months)
Study: 8485328
Drug: Total nutrient
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total nutrient admixture (TNA) at the rate of 4‐5 g lipid/h for 5‐9 days (mean 6.7 days)
Study: 22827935
Drug: Rehabilitative sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitative sports group exercise program for prostate cancer patients, conducted for 15 months starting 8-12 weeks after prostatectomy or combination therapy.
Study: 21375023
Drug: Diovan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diovan (80 mg)
Study: 18037738
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (aspirin, clopidogrel, cilostazol)
Study: 17697815
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (aspirin and clopidogrel)
Study: 2548967
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ultramicronized griseofulvin
Study: 1099692
Drug: Three antimalarial
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three antimalarial drugs
Study: 26641243
Drug: GM-CSF (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (250 μg/m2/d)
Study: 26641243
Drug: Influenza vaccination
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccination (Mutagrip 0.5 ml/d)
Study: 3721047
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural analgesia (L.E.A.)
Study: 16087821
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ergocalciferol (1000 IU) and calcium (1200 mg)
Study: 16087821
Drug: Risedronate sodium
Normalized name: Risedronate Sodium
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate sodium (2.5 mg daily) plus ergocalciferol (1000 IU) and calcium (1200 mg)
Study: 12700718
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam (DZP)
Study: 10582134
Drug: VNR 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VNR 25 mg/m2 + CP 60 mg/m2
Study: 31743184
Drug: Incentive-based game
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive-based game therapy
Study: 23174912
Drug: XELOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX plus bevacizumab (6 cycles) followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression
Study: 26094974
Drug: Sitagliptin 25
Normalized name: SITagliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 25 mg once daily
Study: 3346483
Drug: 351 mg
Normalized name: Erzofri 351 MG in 2.25 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 351 mg of theophylline in 35 mg of ethylenediamine (TE351)
Study: 3346483
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of theophylline in 300 mg of propxyphylline and 300 mg of diprophylline (TPD)
Study: 29270914
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block (ISB) with 20 mL of levobupivacaine 0.25% and epinephrine 5 µg·mL‐1
Study: 29270914
Drug: Combined infraclavicular-suprascapular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined infraclavicular-suprascapular blocks (ICB-SSB) with 20 mL of levobupivacaine 0.25% and 10 mL for SSB
Study: 26922549
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin treatment (rosuvastatin 20‐40 mg daily)
Study: 26922549
Drug: Less aggressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less aggressive statin treatment (simvastatin 20‐40 mg daily)
Study: 22790642
Drug: Once-daily tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tadalafil 5 mg (with possible down-titration to 2.5 mg)
Study: 18214942
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (IF) 2 mg/kg nebulized by hood three times daily
Study: 18214942
Drug: Placebo nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebulized by hood three times daily
Study: 18214942
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (IF)
Study: 17064621
Drug: RFA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFA therapy combined with suture and ligation surgery (SL group, n = 15)
Study: 17064621
Drug: RFA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFA therapy without suture and ligation surgery (non-SL group, n = 15)
Study: 1829902
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg UK 79300
Study: 1829902
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg UK 79300
Study: 10333643
Drug: Oral transmission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmission of strongyloidiasis
Study: 7710623
Drug: Bone graft
Normalized name: Bone graft material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone graft and implant placement in the routine group (20 patients)
Study: 7710623
Drug: Bone graft
Normalized name: Bone graft material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone graft and implant placement in the development group (10 patients)
Study: 7710623
Drug: Bone graft
Normalized name: Bone graft material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone graft and implant placement (both groups)
Study: 901625
Drug: BM 15.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM 15.075 (0.2 g t.i.d.)
Study: 27151908
Drug: Standard syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard syringe injection
Study: 27151908
Drug: Both injection
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both injection techniques
Study: 20410150
Drug: Sit-to-stand training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit-to-stand training (15 minutes each session, in addition to 30 minutes of general physical therapy three times a week for four weeks)
Study: 16310974
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus CM
Study: 8981202
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg three times daily)
Study: 26194935
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg daily for 28 days
Study: 20515216
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (psychotherapy and pharmacotherapy)
Study: 20515216
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral analysis system of psychotherapy (monotherapy)
Study: 20515216
Drug: Nefazodone (monotherapy)
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nefazodone (monotherapy)
Study: 16862549
Drug: Low-energy laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy laser intervention applied for 5 days following the start of chemotherapy.
Study: 12132977
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 7 weeks)
Study: 7572947
Drug: B subunit‐killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit‐killed whole cell (BS‐WC) or killed whole cell‐only (WC) oral cholera vaccines
Study: 1981748
Drug: mifentidine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: mifentidine 20 mg at night
Study: 6452464
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of oral tetracycline twice daily
Study: 25087839
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 25 mg BIW during Cycle 2 after relapse
Study: 2576322
Drug: Caffeine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (10 mg/kg)
Study: 15076238
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r-hGH) at a dose of 4 mg daily (DD)
Study: 15076238
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r-hGH) at a dose of 4 mg on alternate days (AD)
Study: 2887418
Drug: Isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐mononitrate (Imdur) 60mg once daily
Study: 24076415
Drug: Ever daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ever daily smoking
Study: 24076415
Drug: Age at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age at diagnosis for ever daily smokers
Study: 9717593
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg i.v.)
Study: 11731754
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg i.v.) followed by Ketorolac (30 mg)
Study: 11731754
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg i.v.)
Study: 9040549
Drug: Similac with
Normalized name: Similac with Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similac with Iron (iron approximately 215 mumol/L or 12 mg/L)
Study: 2889255
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily at bedtime for 4 weeks
Study: 19652072
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg/d
Study: 26327301
Drug: Siltuximab (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab (11 mg/kg administered intravenously every 3 weeks, or every 6 weeks at investigator's discretion)
Study: 23204550
Drug: Neridronate 100
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 100 mg i.v. infusion given four times over 10 days
Study: 21753156
Drug: LY2334737 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2334737 monotherapy (40 mg)
Study: 21753156
Drug: LY2334737 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2334737 in combination with erlotinib (100 mg)
Study: 21753156
Drug: LY2334737 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2334737 monotherapy
Study: 21753156
Drug: LY2334737 drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2334737 drug formulations
Study: 19192477
Drug: Intramuscular second-generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular second-generation antipsychotics (SGAs)
Study: 24267729
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and aspirin
Study: 18664984
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (CIP) for 6-8 weeks
Study: 18664984
Drug: Topical framycetin-gramicidin-dexamethasone
Normalized name: framycetin / gramicidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical framycetin-gramicidin-dexamethasone (FGD) for 6-8 weeks
Study: 14756388
Drug: Propacetamol 2
Normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 2 g
Study: 15976212
Drug: Acetaminophen 1
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 g and Propacetamol 2 g
Study: 18254326
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray
Study: 3920066
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) solution
Study: 8765824
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (beclomethasone dipropionate (BD) ointment)
Study: 1913269
Drug: Conventional ragweed
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ragweed preparation (Pool 2)
Study: 27019001
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg and Everolimus 10 mg, both once daily for 4 weeks (1 cycle)
Study: 24285427
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg vitamin K1 orally thrice weekly
Study: 18210952
Drug: High compression
Normalized name: BANDAGE,HIGH COMPRESSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: High compression therapy alone
Study: 15526982
Drug: triptorelin (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: triptorelin (GnRH agonist)
Study: 15526982
Drug: ganirelix (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganirelix (GnRH antagonist)
Study: 9591441
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate cream or ointment applied to lesional skin twice daily for 7-19 days
Study: 7814359
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment (3-6 months)
Study: 7814359
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment (6-24 months)
Study: 28498853
Drug: DAR-901 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAR-901 (1 mg)
Study: 26071347
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of HPV-16/18 vaccine
Study: 26071347
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV-16/18 vaccine
Study: 26071347
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of HPV-16/18 vaccine
Study: 26071347
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV-16/18 vaccine (second dose at 6 months)
Study: 26071347
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV-16/18 vaccine (second dose at 1 month)
Study: 22162639
Drug: Oxy-ER (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy-ER (5 mg)
Study: 22162639
Drug: Oxy-CRF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy-CRF (5 mg)
Study: 22162639
Drug: Oxy-CRF (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy-CRF (40 mg)
Study: 22162639
Drug: Oxy-CRF (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy-CRF (40 mg) after high-fat breakfast
Study: 12567387
Drug: HFA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA treatment
Study: 12567387
Drug: Gastrointestinal absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal absorption of BDP
Study: 12567387
Drug: 17‐BMP metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17‐BMP metabolism
Study: 12567387
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration of BDP
Study: 8710419
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment with levamisole every 4 months
Study: 8710419
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment with levamisole at two 6-monthly intervals
Study: 8710419
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment with levamisole once in 1 year
Study: 2000046
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + C 20 mg/100 mg
Study: 2000046
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + C 10 mg/200 mg
Study: 2000046
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + C 20 mg/200 mg
Study: 2000046
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + C 10 mg/200 mg and E + C 20 mg/100 mg
Study: 6392050
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg molsidomine
Study: 6393621
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg molsidomine
Study: 6393621
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg and 6 mg molsidomine
Study: 6393621
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg molsidomine administered 5-6 times daily or 4-6 mg applied 4-5 times daily
Study: 3402013
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral premedication (meperidine 1.5 mg.kg‐1, diazepam 0.15 mg.kg‐1, atropine 0.02 mg.kg‐1)
Study: 27147617
Drug: Formoterol (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (54 μg)
Study: 23727135
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 receptor occupancy levels
Study: 23727135
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 receptor occupancy cut-off point
Study: 16432682
Drug: Quetiapine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (50 mg)
Study: 9505989
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg)
Study: 1321654
Drug: Haloperidol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3 mg)
Study: 30519898
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen
Study: 21343383
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral capsules, twice daily for 18 days)
Study: 16832318
Drug: dexmethylphenidate extended-release
Normalized name: dexmethylphenidate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmethylphenidate extended-release (d-MPH-ER)
Study: 12708604
Drug: Dexibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 800 mg daily
Study: 20525840
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg daily
Study: 10362151
Drug: Spermicidal film
Normalized name: lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermicidal film containing 72 mg of nonoxynol-9 per film
Study: 10362151
Drug: Foaming tablet
Normalized name: Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foaming tablet containing 100 mg of nonoxynol-9 per tablet
Study: 7042364
Drug: Indoprofen (IP)
Normalized name: Neoprofen
DrugBank: Indoprofen (DB08951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (IP) 800 mg/die
Study: 26272770
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg, every 3 weeks for six cycles) with neoadjuvant chemotherapy
Study: 16598591
Drug: Isosorbide-dinitrate (ISDN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-dinitrate (ISDN) 20 mg b.i.d.
Study: 15224025
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g as 20-minute bolus before skin incision, followed by continuous infusion of 400 mg/h, with 500 mg added to priming in on-pump patients)
Study: 15224025
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution of equivalent volume)
Study: 27062948
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment as usual, delayed treatment (DT) control
Study: 25690404
Drug: Pulsed RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed RF EMF exposure (900 MHz, 2 Hz pulse, 20 Hz Gaussian low-pass filter, spatial peak absorption of 2 W/kg averaged over 10 g) for 30 minutes prior to sleep
Study: 12712239
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated) 24 micro g/kg per hour for 96 h
Study: 10344368
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol with cyclic addition of noretisterone acetate (n = 13)
Study: 24140142
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection
Study: 18468378
Drug: Drug reimbursement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug reimbursement rate reduction policy
Study: 15998783
Drug: Pancreatic polypeptide
Normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic polypeptide (PP) infusion at 2.25 pmol/kg.min
Study: 7871082
Drug: diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 0.2 mg/kg
Study: 7871082
Drug: lorazepam 0.038
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 0.038 mg/kg